Regeneron Pharmaceuticals, Inc. $REGN Stock: Parcion Private Wealth LLC Raises Stake

Posted by Geri Gentry on Nov 1st, 2026

Parcion Private Wealth LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 55.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,589 shares of the biopharmaceutical company’s stock after buying an additional 567 shares during the quarter. Parcion Private Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $1,205,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. bought a new position in Regeneron Pharmaceuticals during the second quarter worth $5,682,636,000. Legal & General Group Plc bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $473,872,000. Bank of New York Mellon Corp bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $472,950,000. Deutsche Bank AG acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $323,249,000. Finally, Man Group plc acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $272,460,000. Institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the transaction, the executive vice president owned 12,003 shares of the company’s stock, valued at $10,291,252.17. The trade was a 8.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 8,093 shares of company stock worth $6,506,845. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $927.89 on Friday. The company has a market capitalization of $95.54 billion, a P/E ratio of 20.49, a price-to-earnings-growth ratio of 1.57 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $935.35. The business has a 50-day simple moving average of $793.30 and a two-hundred day simple moving average of $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. The firm’s revenue was up 36.3% on a year-over-year basis. During the same period last year, the firm earned $11.83 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current fiscal year.

Analyst Ratings Changes

REGN has been the topic of a number of research reports. Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $660.00 to $978.00 in a research note on Thursday, October 15th. Finally, Sanford C. Bernstein boosted their price objective on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a “market perform” rating in a report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $850.83.

Check Out Our Latest Stock Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.